The combination regimen of paclitaxel (Taxol) and cisplatin (Platinol) for non–small-cell lung cancer has shown improved response rates in some phase II trials, and because of its safety profile, it could offer patients with this
M. Tonato, MD
Advertisement
Articles by M. Tonato, MD
Advertisement
Latest Updated Articles
- Quality-of-Life Improvement in Patients Receiving Paclitaxel/Platinum Regimens
Published: September 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Classifying High-Risk Patients With NDMM
4
Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva
5
